grant

Sortase Peptide Technology: Enzymatic Site-specific Bioconjugation to Improve Antibody Drug Conjugate Production and Performance [ 2012 - 2015 ]

Also known as: Antibody drug conjugates for the treatment of cancer

Research Grant

[Cite as http://purl.org/au-research/grants/nhmrc/1039017]

Researchers: A/Pr Christoph Hagemeyer (Principal investigator)

Brief description Cancer is characterised by uncontrolled cell growth, leading to invasion and destruction of adjacent tissues. It is a major cause of death in Australia. Targeted drug delivery is an attractive therapeutic strategy that has the potential to lower systemic drug concentrations and reduce side effects. We are developing more efficient cancer drugs.

Funding Amount $AUD 402,046.53

Funding Scheme Development Grants

Notes Development Grant

Click to explore relationships graph
Identifiers
Viewed: [[ro.stat.viewed]]